Last reviewed · How we verify
Azosemid (AZOSEMIDE)
Azosemid (generic name: AZOSEMIDE) is a azosemide drug. It is currently in Phase 3 development for Congestive heart failure.
Azosemide works by inhibiting the reabsorption of sodium and chloride ions in the kidneys.
Azosemide, a small molecule drug in the azosemide class, is used to treat Congestive heart failure. Its mechanism of action is not well-documented, but it is believed to work by inhibiting the reabsorption of sodium and chloride ions in the kidneys, leading to increased urine production and reduced fluid buildup in the body. The commercial status of azosemide is unclear, but it is not widely available in the US market. Key safety considerations include its low bioavailability of 10%, which may affect its efficacy. Further research is needed to fully understand its pharmacological properties.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | AZOSEMIDE |
|---|---|
| Drug class | azosemide |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Think of it like a sponge: when you squeeze a sponge, water comes out. Azosemide helps the kidneys squeeze out excess water and salt by blocking the tiny tubes where they're reabsorbed, allowing more to be excreted in the urine.
Approved indications
- Congestive heart failure
Common side effects
- Cardiac failure
- Renal impairment
- Cardiac failure chronic
- Hepatic function abnormal
- Cerebral infarction
- Blood pressure decreased
- Concomitant disease aggravated
- Brain natriuretic peptide increased
- Pulmonary arterial hypertension
- Altered state of consciousness
- Cardiac failure acute
- Right ventricular failure
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Azosemid CI brief — competitive landscape report
- Azosemid updates RSS · CI watch RSS
Frequently asked questions about Azosemid
What is Azosemid?
How does Azosemid work?
What is Azosemid used for?
What is the generic name of Azosemid?
What drug class is Azosemid in?
What development phase is Azosemid in?
What are the side effects of Azosemid?
Related
- Drug class: All azosemide drugs
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Congestive heart failure
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing